Arigenx SE is a pharmaceutical company based in the Netherlands, with a medium ESG risk rating score of 24.8. Specializing in antibody engineering technology, Arigenx focuses on treating rare autoimmune diseases. Its flagship product, Vyvgart (efgartigimod), was approved in the US in December 2021 for generalized myasthenia gravis, with subsequent approvals in Europe and Japan in 2022. Explore Arigenx's innovative solutions for autoimmune disorders.